Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia:: a stable isotope study

被引:0
|
作者
Frénais, R
Ouguerram, K
Maugeais, C
Marchini, JS
Benlian, P
Bard, JM
Magot, T
Krempf, M [1 ]
机构
[1] Hotel Dieu, Grp Metab, Ctr Rech Nutr Humaine, Nantes, France
[2] Sch Med Ribeirao Preto, Div Clin Nutr, Ribeirao Preto, Brazil
[3] Hop St Antoine, Serv Biochim, F-75571 Paris, France
[4] Hotel Dieu, Biochim Lab, Fac Pharm, Nantes, France
[5] Hotel Dieu, Clin Endocrinol, Nantes, France
关键词
heterozygous familial hypercholesterolemia; stable isotope; kinetic analysis; apo AI; HDL;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heterozygous familial hypercholesterolemia (FH) is associated with a moderate decrease of plasma apoA-I and HDL-cholesterol levels. The aim of the study was to test the hypothesis that these abnormalities were related to an increase of HDL-apoA-I fractional catabolic rate (FCR), We performed a 14-h infusion of [5,5,5-H-2(3)]leucine in seven control subjects and seven heterozygous FH patients (plasma total cholesterol 422 +/- 27 vs. 186 +/- 42 mg/dL, P < 0.001, respectively), Plasma apoA-I concentration was not changed in FH compared to controls (respectively 115 +/- 18 vs. 122 +/- 15 mg-/dL, NS), and HDL-cholesterol level was decreased (37 +/- 7 vs. 46 +/- 19 mg/dL, NS), Kinetics of HDL metabolism were modeled as a single compartment as no differences were observed between HDL2 and HDL3 subclasses. Both mean apoA-I FCR and absolute production rate (APR) were increased in FH (respectively, 0.36 +/- 0.14 vs. 0.22 +/- 0.05 pool/d, P < 0.05, and 18.0 +/- 7.7 and 11.2 +/- 2.3 mg/kg/d, P < 0.05), Higher HDL-triglyceride and HDL apoE levels were observed in patients with heterozygous FH, (Respectively 19 +/- 8 vs. 8 +/- 3 mg/dL, P < 0.05, and 5.3 +/- 0.8 vs. 3.7 +/- 0.9 mg/dL, P < 0.05). We conclude that the catabolism of HDL-apoA-I is increased in heterozygous FH patients, However, plasma apoA-I concentration was maintained because of an increased HDL-apoA-I production rate.
引用
收藏
页码:1506 / 1511
页数:6
相关论文
共 35 条
  • [21] Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study
    Kolovou, Vana
    Katsiki, Niki
    Makrygiannis, Stamatis
    Mavrogieni, Sophie
    Karampetsou, Nikoletta
    Manolis, Athanasios
    Melidonis, Andreas
    Mikhailidis, Dimitri P.
    Kolovou, Genovefa D.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 26 (01) : 51 - 58
  • [22] The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions
    Carneiro, Marcia M.
    Miname, Marcio H.
    Gagliardi, Ana C.
    Pereira, Carolina
    Pereira, Alexandre C.
    Krieger, Jose E.
    Maranhao, Raul C.
    Santos, Raul D.
    ATHEROSCLEROSIS, 2012, 221 (01) : 268 - 274
  • [23] Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison
    Zheng, Bo
    Goto, Shinya
    Clementi, Regina
    Feaster, John
    Duffy, Danielle
    Dalitz, Penelope
    Airey, Jolanta
    Korjian, Serge
    Tortorici, Michael A.
    Roberts, John
    Gibson, C. Michael
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (10): : 2331 - 2341
  • [24] Reduction of LDL-C levels with AMG-145, a monoclonal antibody against PCSK9, in heterozygous familial hypercholesterolemia: the RUTHERFORD study
    Rhainds, David
    Tardif, Jean-Claude
    CLINICAL LIPIDOLOGY, 2013, 8 (05) : 513 - 517
  • [25] Association between the ratio of high-density lipoprotein cholesterol to apolipoprotein A-I and in-stent neoatherosclerosis: an optical coherence tomography study
    Gu, Ning
    Zeng, Yu
    Long, Xianping
    Liu, Zhijiang
    Wang, Zhenglong
    Zhang, Wei
    Yang, Du
    Yuan, Jingsong
    Chen, Lei
    Zhao, Ranzun
    Shi, Bei
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2024, 15 (01) : 116 - 127
  • [26] Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes:: a stable isotope kinetic study
    Duvillard, L
    Pont, F
    Florentin, E
    Galland-Jos, C
    Gambert, P
    Vergès, B
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2000, 30 (08) : 685 - 694
  • [27] Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin
    Tani, Shigemasa
    Takahashi, Atsuhiko
    Nagao, Ken
    Hirayama, Atsushi
    HEART AND VESSELS, 2015, 30 (06) : 762 - 770
  • [28] Effect of Royal Jelly Intake on Serum Glucose, Apolipoprotein A-I 0 (ApoA-I), Apolipoprotein B (ApoB) and ApoB/ApoA-I Ratios in Patients with Type 2 Diabetes: A Randomized, Double-Blind Clinical Trial Study
    Khoshpey, Basemeh
    Djazayeri, Shima
    Amiri, Fatemehsadat
    Malek, Mojtaba
    Hosseini, Agha Fateme
    Hosseini, Sharieh
    Shidfar, Shahrzad
    Shidfar, Farzad
    CANADIAN JOURNAL OF DIABETES, 2016, 40 (04) : 324 - 328
  • [29] Evaluation of Potential Antiplatelet Effects of CSL112, a Novel Formulation of Human Apolipoprotein A-I: Results From a Phase 2a Study
    Gurbel, Paul A.
    Bliden, Kevin P.
    D'Andrea, Denise M.
    Henderson, Karen W.
    Alexander, John H.
    Tantry, Udaya S.
    Shear, Charles
    Tricoci, Pierluigi
    CIRCULATION, 2013, 128 (22)
  • [30] The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
    Hovingh, G. Kees
    Smits, Loek P.
    Stefanutti, Claudia
    Soran, Handrean
    Kwok, See
    de Graaf, Jacqueline
    Gaudet, Daniel
    Keyserling, Constance H.
    Klepp, Heather
    Frick, Jennifer
    Paolini, John F.
    Dasseux, Jean-Louis
    Kastelein, John J. P.
    Stroes, Erik S.
    AMERICAN HEART JOURNAL, 2015, 169 (05) : 736 - U196